QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will be monitored throughout the study.

NCT Number	NCT06939855
Lead Sponsor	Sun Yat-sen University
Conditions	Bone and Soft Tissue Tumors
Enrollment	45 participants
Start Date	2025-09-28
Primary Completion	2027-05-01 (estimated)
Study Completion	2028-05-01 (estimated)
Updated on ClinicalTrials.gov	2025-11-19